Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Final Results of Anagrelide Controlled-Release (GALE-401) Safety, Efficacy and Pharmacokinetics in Subjects with Myeloproliferative Neoplasms (MPN)-Related Thrombocytosis

Phu V. Troung, MD F.A.C.P., Marc Saltzman, MD, Alberto Bessudo, MD, William Jawien, MD, Roger M. Lyons, MD F.A.C.P., Dmitriy Berenzon, MD, Raul Mena, MD, Nasiema Wingate-Pearse, Olivier Barriere, PhD, Hali E. Beeson, Paul F. Glidden, PhD, Gavin S. Choy, PharmD, MBA, Srdan Verstovsek, MD PhD

Blood (2015) 126 (23): 4074.

https://doi.org/10.1182/blood.V126.23.4074.4074

Published: 2015

Journal Articles

Targeting Pim Kinase Activity with the Novel Small Molecule Inhibitor SGI-1776 Significantly Augments the Efficacy of Cytarabine In Models of Acute Myeloid Leukemia

Kevin R Kelly, MD, Kelli Oberheu, B.S., Ernest Medina, B.S., Claudia M Espitia, MS, Devalingam Mahalingam, MD, PhD, Pietro Taverna, PhD, Gavin S. Choy, PharmD, MBA, Steffan T Nawrocki, PhD, Francis J. Giles, MB, MD, FRCPI, FRCPath, Jennifer S Carew, PhD

Blood (2010) 116 (21): 3253.

https://doi.org/10.1182/blood.V116.21.3253.3253

Published: 2010

Journal Articles

SGI-110, a Novel Second Generation Potent DNA Methylation Inhibitor, In Development for the Treatment of MDS and AML. Preclinical Safety, Pharmacokinetics, and DNA Methylation Results of a Low Volume Subcutaneous (SC) Formulation

Jason Scholl, PhD, Rajashree Joshi-Hangal, PhD, Roger Inloes, PhD, Chongtie Shi, PhD, Pietro Taverna, PhD, Gavin S. Choy, PharmD, MBA, Sanjeev Redkar, PhD, Mohammad Azab, MD, MSC, MBA

Blood (2010) 116 (21): 1872.

https://doi.org/10.1182/blood.V116.21.1872.1872

Published: 2010

Journal Articles

Marqibo (Vincristine Sulfate Liposomes Injection, OPTISOME™) Concentrates Vincristine in Tumor Tissue and Lymphoid Malignancy Oriented Tissues in Tumor-Bearing Mice.

Pieter R. Cullis, Hagop Kantarjian, Frederick Appelbaum, Susan O’Brien, May Wong, Gavin S. Choy, Steven R. Deitcher

Blood (2007) 110 (11): 1403.

https://doi.org/10.1182/blood.V110.11.1403.1403

Published: 2007

Journal Articles

Marqibo (Vincristine Sulfate Liposomes Injection (OPTISOME™) Demonstrates Activity in Patients with Relapsed and Refractory Peripheral T-Cell Lymphoma.

M. Alma Rodriguez, MD, Jane N. Winter, MD, Biao Lu, PhD, Gary Huang, MD, Gavin S. Choy, PharmD, Steven R. Deitcher, MD

Blood (2007) 110 (11): 4466.

https://doi.org/10.1182/blood.V110.11.4466.4466

Published: 2007

Journal Articles

Safety and Efficacy of Marqibo (Vincristine Sulfate Liposomes Injection, OPTISOME™) in for the Treatment of Adults with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL).

Deborah A. Thomas, MD, Hagop M. Kantarjian, MD, Wendy Stock, MD, Leonard Heffner, MD, Alexandra Tredinnick, Baio Lu, Gavin S. Choy, Steven R. Deitcher, MD, Susan M. O’Brien, MD

Blood (2007) 110 (11): 858.

https://doi.org/10.1182/blood.V110.11.858.858

Published: 2007

Journal Articles

A Phase I Study of Talvesta® (Talotrexin) in Relapsed or Refractory Leukemia or Myelodysplastic Syndrome.

Francis Giles, MD, David A. Rizzieri, MD, Solly George, RN, Wendy Stock, MD, Jeannie Fontanilla, BS, Gavin S. Choy, PharmD, Gregory I. Berk, MD

Blood (2006) 108 (11): 1968.

https://doi.org/10.1182/blood.V108.11.1968.1968

Published: 2006

NARROW

Final Results of Anagrelide Controlled-Release (GALE-401) Safety, Efficacy and Pharmacokinetics in Subjects with Myeloproliferative Neoplasms (MPN)-Related Thrombocytosis

Targeting Pim Kinase Activity with the Novel Small Molecule Inhibitor SGI-1776 Significantly Augments the Efficacy of Cytarabine In Models of Acute Myeloid Leukemia

SGI-110, a Novel Second Generation Potent DNA Methylation Inhibitor, In Development for the Treatment of MDS and AML. Preclinical Safety, Pharmacokinetics, and DNA Methylation Results of a Low Volume Subcutaneous (SC) Formulation

Marqibo (Vincristine Sulfate Liposomes Injection, OPTISOME™) Concentrates Vincristine in Tumor Tissue and Lymphoid Malignancy Oriented Tissues in Tumor-Bearing Mice.

Marqibo (Vincristine Sulfate Liposomes Injection (OPTISOME™) Demonstrates Activity in Patients with Relapsed and Refractory Peripheral T-Cell Lymphoma.

Safety and Efficacy of Marqibo (Vincristine Sulfate Liposomes Injection, OPTISOME™) in for the Treatment of Adults with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL).

A Phase I Study of Talvesta® (Talotrexin) in Relapsed or Refractory Leukemia or Myelodysplastic Syndrome.

Email alerts

ASH Publications

American Society of Hematology

Final Results of Anagrelide Controlled-Release (GALE-401) Safety, Efficacy and Pharmacokinetics in Subjects with Myeloproliferative Neoplasms (MPN)-Related Thrombocytosis

Targeting Pim Kinase Activity with the Novel Small Molecule Inhibitor SGI-1776 Significantly Augments the Efficacy of Cytarabine In Models of Acute Myeloid Leukemia

SGI-110, a Novel Second Generation Potent DNA Methylation Inhibitor, In Development for the Treatment of MDS and AML. Preclinical Safety, Pharmacokinetics, and DNA Methylation Results of a Low Volume Subcutaneous (SC) Formulation

Marqibo (Vincristine Sulfate Liposomes Injection, OPTISOME™) Concentrates Vincristine in Tumor Tissue and Lymphoid Malignancy Oriented Tissues in Tumor-Bearing Mice.

Marqibo (Vincristine Sulfate Liposomes Injection (OPTISOME™) Demonstrates Activity in Patients with Relapsed and Refractory Peripheral T-Cell Lymphoma.

Safety and Efficacy of Marqibo (Vincristine Sulfate Liposomes Injection, OPTISOME™) in for the Treatment of Adults with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL).

A Phase I Study of Talvesta® (Talotrexin) in Relapsed or Refractory Leukemia or Myelodysplastic Syndrome.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only